New fatty liver drug tested in patients with liver damage
NCT ID NCT05917938
First seen Feb 19, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This study tested a single injection of a new drug, NNC0194-0499, in 33 adults with either normal liver function or mild to severe liver impairment. The drug is being developed for non-alcoholic fatty liver disease (NAFLD) and its more serious form, NASH. The main goal was to see how the body processes the drug and whether it is safe in people with different levels of liver function. Results will help determine the right dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APEX Research
München, 81241, Germany
-
Cardiomedicum Sp. z o.o.
Krakow, 30-002, Poland
-
Summit Clinical Research s.r.o.
Bratislava, 83101, Slovakia
-
Summit Clinical Research s.r.o.
Malacky, 901 22, Slovakia
-
Uniwersyteckie Centrum Kliniczne (UCK)
Gdansk, 80-214, Poland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0194-0499
What this could lead to
If successful, this study could help determine safe and effective dosing of NNC0194-0499 for people with liver problems, potentially leading to a treatment for fatty liver disease.
What could go wrong
This is an early Phase 1 study with only 33 participants, focused on safety and drug processing, not on treating the disease. The drug may not work in larger trials or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.